

SCALES TO MEASURE DYSTONIA

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



Disclaimer:

“The European Commission support for the production of this publication does not constitute endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.”

More information on the European Union is available on the Internet (<http://europa.eu>).

Luxembourg: Publications Office of the European Union, 2019

© European Union, 2019

Reproduction is authorised provided the source is acknowledged.

INTRODUCTION TO THE EUROPEAN REFERENCE NETWORK FOR RARE NEUROLOGICAL DISEASES (ERN-RND)

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 64 of Europe's leading expert centers as well as 4 affiliated partners in 24 member states and includes highly active patient organizations. Centers are located in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Slovenia, Spain and Sweden.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinson's disease
- Dystonia, Paroxysmal Disorder and Neurodegeneration with Brain Iron Accumulation
- Frontotemporal Dementia
- Huntington's Disease and other Chorea
- Leukodystrophies

Specific information about the network, the expert centers and the covered diseases can be found on the network's website www.ern-rnd.eu.

Recommendation for clinical use:

The European Reference Network for Rare Neurological Diseases strongly recommends the use of the following scales as best clinical practice for the assessment and rating of Dystonia.

DISCLAIMER

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service.

The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

METHODOLOGY

The recommendations of clinical rating scales for Dystonia was developed by the Disease Group for Dystonia, Paroxysmal Disorders and NBIA of ERN-RND. Scales used in the clinical practice of the Disease Group members were mapped, and the decision on which scales should be proposed was taken by anonymous majority voting.

Disease group for Dystonia, Paroxysmal Disorders and NBIA:

Disease group coordinators:

Javier Perez Sanchez¹⁵; Sylvia Boesch²⁶

Disease group members:

Health care professionals:

Mette Møller¹; Erik Johnsen¹; Erik Hvid Danielsen¹; Laura van de Pol²; Anna De Rosa³; Myriam Carecchio⁴; Roberto Ceravolo⁵; Elisa Unti⁵; Giovanni Palermo⁵; Andrea Mignarri⁶; Antonio Federico⁶; Marie Vidailhet⁷; Aurelie Meneret⁷; Marta Blázquez Estrada⁸; Pierre Kolber⁹; Giorgos Pitsas¹⁰; Christos Koros¹¹; Evangelos Anagnostou¹¹; Leonidas Stefanis¹¹; Heli Helander¹³; Jiri Klempir¹⁴; Sára Davisonová¹⁴; Francisco Grandas¹⁵; Dirk Dressler¹⁶; Alejandra Darling¹⁷; Juan Dario Ortigoza Escobar¹⁷; Eugenia Amato¹⁷; Maria Jose Marti¹⁷; Yaroslau Compta¹⁷; Marta Skowronska¹⁸; Michal Sobstyl¹⁸; Antonio Elia¹⁹; Giovanna Zorzi¹⁹; Roberto Cilia¹⁹; Roberto Eleopra¹⁹; Alberto Albanese²⁰; Giulia Giannini²¹; Luca Solina²¹; Duccio Maria Cordelli²¹; Caterina Garone²¹; Veronica Di Pisa²¹; Anna Fetta²¹; Richard Walsh²²; Kathleen Gorman²²; Aoife Mahony²²; Ana Rodríguez²³; Soledad Serrano²³; Franziska Höpfner²⁴; Thomas Klopstock²⁴; Jeroen Vermeulen²⁵; Philipp Mahlknecht²⁶; Daniel Boesch²⁶; Wolfgang Nachbauer²⁶; Krista Ladzovska²⁷; Ramona Valante²⁷; Elina Pucite²⁷; Enrico Bertini²⁸; Francesco Nicita²⁸; Giacomo Garone²⁸; Bart Post²⁹; Michèl Willemsen²⁹; Anke Snijders²⁹; Manuel Dafotakis³⁰; Rocío García-Ramos³¹; Maria Judit Molnar³²; Marek Baláž³³; Martina Bočková³³; Ognjana Burgazlieva³⁴; Andras Salamon³⁵; Aive Liigant³⁶; Pawel Tacik³⁷; Fran Borovecki³⁸; Ivana Jurjevic³⁸; Malgorazate Dec-Cwiek³⁹; Katarzyna Sawczynska³⁹; Alexander Münchau⁴⁰; Katja Lohmann⁴⁰; Norbert Brüggemann⁴⁰; Sebastian Löns⁴⁰; Tobias Bäumer⁴⁰; Ebba Lohmann⁴¹; Kathrin Grundmann⁴¹; Thomas Gasser⁴¹; Hendrik Rosewich⁴¹; Bernhard Landwehrmeier⁴²; Thomas Musacchio⁴³; Martin Reich⁴³; Marina de Koning-Tijssen⁴⁴; Tom de Koning⁴⁴; Damjan Osredkar⁴⁵; Maja Kojovic⁴⁵; Kinga Hadzsiev⁴⁶; Norbert Kovacs⁴⁶; Belén Pérez Dueñas⁴⁷; Maria Victoria Gonzalez Martinez⁴⁷; Silvia Jesús Maestre⁴⁸; Astrid Daniela Adarmes⁴⁸; Pablo Mir⁴⁸; Elena Ojeda Lepe⁴⁸; Marta Correa⁴⁸

Patient representative:

Monika Benson¹²

¹Aarhus University Hospital, Denmark; ²Amsterdam UMC - Amsterdam University Medical Center, Netherlands; ³AOU - Federico II University Hospital, Naples, Italy; ⁴AOU - University Hospital Padua, Italy; ⁵AOU - University Hospital Pisa, Italy; ⁶AOU - University Hospital Siena, Italy; ⁷APHP - Reference Centre for Rare Diseases 'Neurogenetics', Pitié-Salpêtrière Hospital, Paris, France; ⁸Asturias Central University Hospital, Oviedo, Spain; ⁹CHL - Luxembourg Hospital Center, Luxembourg; ¹⁰Cyprus Institute of Neurology and Genetics, Egkomi, Cyprus; ¹¹Eginitio Hospital, National and Kapodistrian University of Athens, Greece; ¹²ePAG representative; ¹³Finland Consortium: University Hospitals in Oulu,

Tampere and Helsinki, Finland; ¹⁴General University Hospital Prague, Czech Republic; ¹⁵Gregorio Marañón General University Hospital, Madrid, Spain; ¹⁶Hannover Medical School, Germany; ¹⁷Hospital Clinic Barcelona and Sant Joan de Déu Hospital, Barcelona, Spain; ¹⁸Institute of Psychiatry and Neurology, Warsaw, Poland; ¹⁹IRCCS - Foundation of the Carlo Besta Neurological Institute, Milan, Italy; ²⁰IRCCS - Humanitas Clinical Institute of Rozzano, Milan, Italy; ²¹IRCCS - Institute of Neurological Sciences of Bologna, Italy; ²²Irish Consortium: Tallaght University Hospital and Children's Health Ireland; ²³La Paz University Hospital, Madrid, Spain; ²⁴Ludwig Maximilian University Hospital, Munich, Germany; ²⁵Maastricht University Medical Center, Netherlands; ²⁶Medical University Innsbruck, Austria; ²⁷Pauls Stradins Clinical University Hospital, Riga, Latvia; ²⁸Pediatric Hospital Bambino Gesù, Rome, Italy; ²⁹Radboud University Medical Centre, Nijmegen, Netherlands; ³⁰RWTH - University Hospital Aachen, Germany; ³¹San Carlos Clinical Hospital, Madrid, Spain; ³²Semmelweis University, Budapest, Hungary; ³³St. Anne's University Hospital Brno, Czech Republic; ³⁴St. Naum University Neurological Hospital, Sofia, Bulgaria; ³⁵Szent-Györgyi Albert Medical Center, Szeged, Hungary; ³⁶Tartu University Hospital, Estonia; ³⁷University Hospital Bonn, Germany; ³⁸University Hospital Center Zagreb, Croatia; ³⁹University Hospital in Krakow, Poland; ⁴⁰University Hospital Schleswig-Holstein, Lübeck, Germany; ⁴¹University Hospital Tübingen, Germany; ⁴²University Hospital Ulm, Germany; ⁴³University Hospital Würzburg, Germany; ⁴⁴University Medical Center Groningen, Netherlands; ⁴⁵University Medical Centre Ljubljana, Slovenia; ⁴⁶University of Pécs, Hungary; ⁴⁷Vall d'Hebron University Hospital, Barcelona, Spain; ⁴⁸Virgen del Rocio University Hospital, Sevilla, Spain

Endorsement process:

- Mapping of used disease scales by disease group: June to December 2018
- Survey to decide on scales by anonymous majority voting: 31.01. – 24.02.2019
- Consent on document by whole disease group: 26.03.2019
- Endorsement on updated recommendations by whole disease group: 11.10.2024

RECOMMENDED SCALES

Domain	Scale
Generalised dystonia	<u>Fahn-Marsden Dystonia Rating Scale:</u> Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. <i>Neurology</i> 1985;35:73–77.
Generalised dystonia in children	<u>The Movement Disorder-Childhood Rating Scale:</u> Battini R, Sgandurra G, Petacchi E, Guzzetta A, Di Pietro R, Giannini MT, Leuzzi V, Mercuri E, Cioni G. Movement disorder-childhood rating scale: Reliability and validity. <i>Pediatr Neurol</i> 2008;39:259-265
Blepharospasm	Defazio G, Hallett, M, Jinnah HA, Stebbins GT, Gigante AF, Ferrazzano G, Conte A, Fabbrini G, Berardelli A. <u>Development and Validation of a Clinical Scale for Rating the Severity of Blepharospasm.</u> <i>Mov Disord.</i> 2015 April; 30(4): 525–530. Battini R, Sgandurra G, Petacchi E, Guzzetta A, Di Pietro R, Giannini MT, Leuzzi V, Mercuri E, Cioni G. <u>Movement disorder-childhood rating scale: Reliability and validity.</u> <i>Pediatr Neurol</i> 2008;39:259-265
Cervical Dystonia	Toronto Western Spasmodic Torticollis Rating Scale for cervical dystonia <ul style="list-style-type: none"> - Consky, E, Basinski, A, Belle, L, Ranaway, R, and Lang, AE. The <u>Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (abstract).</u> <i>Neurology.</i> 1990; 40: 445 - Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. <u>Therapy with Botulinum Toxin.</u> New York, NY: Marcel Dekker, Inc.:1994;211-237
Laryngeal Dystonia	<u>Vocal Performance Questionnaire (VPQ):</u> Carding PN, Horsley IA, Docherty GJ. A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. <i>J Voice.</i> 1999; 13:72–104.
Degree of Neurological Disability	<u>Modified Rankin Scale (mRS):</u> Rankin J. Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis. <i>Scottish Medical Journal.</i> 1957;2(5):200-215.



https://ec.europa.eu/health/ern_en



European
Reference
Network

for rare or low prevalence
complex diseases

Network
Neurological Diseases
(ERN-RND)

Coordinator
Universitätsklinikum
Tübingen – Deutschland

www.ern-rnd.eu

Co-funded by the European Union

